Visceral adiposity syndrome

Diabetology and Metabolic Syndrome

Volumn 8, Issue 1, 2016, Pages

  Lopes, Heno F ^a,b   Corrêa Giannella, Maria Lúcia ^b   Consolim Colombo, Fernanda M ^a,b   Egan, Brent M ^c  

^a UNIVERSIDADE NOVE DE JULHO   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Adipocytokines; Adipose tissue; Insulin resistance; Parasympathetic activity; Sympathetic activity; Visceral obesity syndrome

Indexed keywords

AUTONOMIC NERVOUS SYSTEM; DNA METHYLATION; EMBRYO DEVELOPMENT; GENETIC ASSOCIATION; HUMAN; INFLAMMATION; INSULIN RESISTANCE; INTRAABDOMINAL FAT; LOW BIRTH WEIGHT; MALNUTRITION; METABOLIC DISORDER; MICROFLORA; NEUROMODULATION; NUCLEAR REPROGRAMMING; OVERNUTRITION; PRIORITY JOURNAL; REVIEW; VISCERAL ADIPOSITY SYNDROME;

EID: 84978698171     PISSN: None     EISSN: 17585996     Source Type: Journal    
DOI: 10.1186/s13098-016-0156-2     Document Type: Review

References (79)

1. Enzi G, Busetto L, Inelmen EM, Coin A, Sergi G. Historical perspective: visceral obesity and related comorbidity in Joannes Baptista Morgagni's 'De sedibus et causis morborum per anatomen indagata'. Int J Obes Relat Metab Disord. 2003;27:534-5.
2. Hitzenberger K, Richter-Quittner M. Ein beitrag zum stoffweschsel bei dur vaskulären hypertonie. Wiener Arch Innere Med. 1921;2:189-216.
3. Hitzenberger K. Über den blutdruck bei diabetes mellitus. Wiener Arch Innere Med. 1921;2:461-6.
4. Kylin E. Studien uber das hypertonie-hyperglykamie-hyperurikamiesyndrom. Zentrabl finnere Med Leipz. 1923;8:05-127.
5. Preble WE. Obesity: observations on one thousand cases. Boston Med Surg J. 1923;188:617-21.
6. Himsworth HP. The mechanism of diabetes mellitus. Lancet. 1939;2:1-6.
7. Himsworth HP. The mechanism of diabetes mellitus, II: the control of the blood sugar level. Lancet. 1939;2:65-8.
8. Himsworth HP. The mechanism of diabetes mellitus, II: the control of the blood sugar level (cont). Lancet. 1939;2:118-22.
9. Vague J. La différenciation sexuelle: facteur déterminant des formes de l'obesité. Presse Med 1947; 339-40.
10. Vague J. The degree of masculine differentiation of obesities: a factor determining predisposition to diabetes, atherosclerosis, gout, and uric calculous disease. Am J Clin Nutr. 1956;4:20-34.
11. Albrink MJ, Meigs JW. Interrelationship between skinfold thickness, serum lipids and blood sugar in men. Am J Clin Nutr. 1964;15:255-61.
12. Avogaro P, Crepaldi G, Enzi G, Tiengo A. Associazione di iperlipidemia, diabete mellito e obesità di medio grado. Acta Diabetol Lat. 1967;4:36-41.
13. Haller H. Epidermiology and associated risk factors of hyperlipoproteinemia [Article in German]. Z Gesamte Inn Med. 1977;32:124-8.
14. Singer P. Diagnosis of primary hyperlipoproteinemias (Article in German). Z Gesamte Inn Med. 1977; 32(9):129-33.
15. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37(12):1595-607.
16. Kaplan NM. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med. 1989;149:1514-20.
17. Ferrannini E, Haffner SM, Mitchell BD, Stern MP. Hyperinsulinaemia: the key feature of a cardiovascular and metabolic syndrome. Diabetologia. 1991;34:416-22.
18. Ohlson LO, Larsson B, Svärdsudd K, Welin L, Eriksson H, Wilhelmsen L, Björntorp P, Tibblin G. The influence of body fat distribution on the incidence of diabetes mellitus. 13.5 years of follow-up of the participants in the study of men born in 1913. Diabetes. 1985;34:1055-8.
19. Rexrode KM, Carey VJ, Hennekens CH, Walters EE, Colditz GA, Stampfer MJ, Willett WC, Manson JE. Abdominal adiposity and coronary heart disease in women. JAMA. 1998;280:1843-8.
20. Galassi A, Reynolds K, He J. Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am J Med. 2006;119(10):812-9.
21. Nashar K, Egan BM. Relationship between chronic kidney disease and metabolic syndrome: current perspectives. Diabetes Metab Syndr Obes. 2014;7:421-35.
22. Esposito K, Chiodini P, Colao A, Lenzi A, Giugliano D. Metabolic syndrome and risk of cancer: a systematic review and meta-analysis. Diabetes Care. 2012;35:2402-11.
23. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus: provisional report of a WHO consultation. Diabet Med. 1998;15:539-53.
24. Balkau B, Charles MA. Comment on the provisional report from the WHO consultation: European Group for the Study of Insulin Resistance (EGIR). Diabet Med. 1999;16(5):442-3.
25. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. JAMA. 2001;285(19):2486-97.
26. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome - a new worldwide definition. IDF Epidemiology Task Force Consensus Group. Lancet. 2005;366(9491):1059-62.
27. Wang CC, Goalstone ML, Draznin B. Molecular mechanisms of insulin resistance that impact cardiovascular biology. Diabetes. 2004;53:2735-40.
28. Lebovitz HE, Banerji MA. Point: visceral adiposity is causally related to insulin resistance. Diab Care. 2005;28:2322-5.
29. Semple RK. How does insulin resistance arise, and how does it cause disease? Human genetic lessons. Eur J Endocrinol. 2016;174(5):R209-23.
30. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest. 2006;116:1793-801.
31. Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev. 2000;21:697-738.
32. Odegaard JI, Chawla A. Pleiotropic actions of insulin resistance and inflammation in metabolic homeostasis. Science. 2013;339:172-7.
33. Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest. 2006;116:3015-25.
34. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 2011;11:98-107.
35. Caselli C. Role of adiponectin system in insulin resistance. Mol Genet Metab. 2014;113:155-60.
36. Araújo TG, Oliveira AG, Carvalho BM, Guadagnini D, Protzek AO, Carvalheira JB, Boschero AC, Saad MJ. Hepatocyte growth factor plays a key role in insulin resistance-associated compensatory mechanisms. Endocrinology. 2012;153:5760-9.
37. Yi P, Park JS, Melton DA. Betatrophin: a hormone that controls pancreatic β cell proliferation. Cell. 2013;153:747-58.
38. Shanik MH, Xu Y, Skrha J, Dankner R, Zick Y, Roth J. Insulin resistance and hyperinsulinemia: is hyperinsulinemia the cart or the horse? Diabetes Care. 2008;31(Suppl 2):S262-8.
39. Guo S. Insulin signaling, resistance, and the metabolic syndrome: insights from mouse models into disease mechanisms. J Endocrinol. 2014;220:T1-23.
40. Obici S, Feng Z, Karkanias G, Baskin DG, Rossetti L. Decreasing hypothalamic insulin receptors causes hyperphagia and insulin resistance in rats. Nat Neurosci. 2002;5:566-72.
41. Lee Y, Berglund ED, Yu X, Wang MY, Evans MR, Scherer PE, Holland WL, Charron MJ, Roth MG, Unger RH. Hyperglycemia in rodent models of type 2 diabetes requires insulin-resistant alpha cells. Proc Natl Acad Sci USA. 2014;111:13217-22.
42. Halperin F, Lopez X, Manning R, Kahn CR, Kulkarni RN, Goldfine AB. Insulin augmentation of glucose-stimulated insulin secretion is impaired in insulin-resistant humans. Diabetes. 2012;61:301-9.
43. Kulkarni RN, Brüning JC, Winnay JN, Postic C, Magnuson MA, Kahn CR. Tissue-specific knockout of the insulin receptor in pancreatic beta cells creates an insulin secretory defect similar to that in type 2 diabetes. Cell. 1999;96:329-39.
44. Muniyappa R, Iantorno M, Quon MJ. An integrated view of insulin resistance and endothelial dysfunction. Endocrinol Metab Clin North Am. 2008;37:685-711.
45. Nizar JM, Dong W, McClellan RB, Labarca M, Zhou Y, Wong J, Goens DG, Zhao M, Velarde N, Bernstein D, Pellizzon M, Satlin LM, Bhalla V. Sodium-sensitive elevation in blood pressure is ENaC independent in diet-induced obesity and insulin resistance. Am J Physiol Renal Physiol. 2016;310(9):F812-20.
46. Montani JP, Antic V, Yang Z, Dulloo A. Pathways from obesity to hypertension: from the perspective of a vicious triangle. Int J Obes. 2002;26:S28-38.
47. Vlassara H, Uribarri J. Advanced glycation end products (AGE) and diabetes: cause, effect, or both? Curr Diab Rep. 2014;14:1-10.
48. Shimomura I, Bashmakov Y, Horton JD. Increased levels of nuclear SREBP-1c associated with fatty livers in two mouse models of diabetes mellitus. J Biol Chem. 1999;274:30028-32.
49. Iwasaki Y, Nishiyama M, Taguchi T, Asai M, Yoshida M, Kambyashi M, Terada Y, Hashimoto K. Insulin exhibits short-term anti-inflammatory but long-term proinflammatory effects in vitro. Mol Cell Endocrinol. 2009;298:25-32.
50. Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer. 2012;12:159-69.
51. Renehan AG, Frystyk J, Flyvbjerg A. Obesity and cancer risk: the role of the insulin-IGF axis. Trends Endocrinol Metab. 2006; 17(8):328-36.
52. Godfrey KM, Lillycrop KA, Burdge GC, Gluckman PD, Hanson MA. Epigenetic mechanisms and the mismatch concept of the developmental origins of health and disease. Pediatr Res. 2007;61:5R-10R.
53. Rinaudo P, Wang E. Fetal programming and metabolic syndrome. Annu Rev Physiol. 2012;74:107-30.
54. Skinner MK, Manikkam M, Guerrero-Bosagna C. Epigenetic transgenerational actions of environmental factors in disease etiology. Trends Endocrinol Metab. 2010;21:214-22.
55. Intine RV, Sarras MP Jr. Metabolic memory and chronic diabetes complications: potential role for epigenetic mechanisms. Curr Diab Rep. 2012;12:551-9.
56. Roseboom TJ, Painter RC, van Abeelen AF, Veenendaal MV, de Rooij SR. Hungry in the womb: what are the consequences? Lessons from the Dutch famine. Maturitas. 2011;70:141-5.
57. Tobi EW, Lumey LH, Talens RP, Kremer D, Putter H, Stein AD, Slagboom PE, Heijmans BT. DNA methylation differences after exposure to prenatal famine are common and timing- and sex-specific. Hum Mol Genet. 2009;18:4046-53.
58. Yarbrough DE, Barrett-Connor E, Kritz-Silverstein D, Wingard DL. Birth weight, adult weight, and girth as predictors of the metabolic syndrome in postmenopausal women: the Rancho Bernardo Study. Diab Care. 1998;21:1652-8.
59. Ramadhani MK, Grobbee DE, Bots ML, Castro Cabezas M, Vos LE, et al. Lower birth weight predicts metabolic syndrome in young adults: the Atherosclerosis Risk in Young Adults (ARYA)-study. Atherosclerosis. 2006;184:21-7.
60. Tremaroli V, Bäckhed F. Functional interactions between the gut microbiota and host metabolism. Nature. 2012;489:242-9.
61. Round JL, Mazmanian SK. The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol. 2009;9:313-23.
62. Brandsma E, Houben T, Fu J, Shiri-Sverdlov R, Hofker MH. The immunity-diet-microbiota axis in the development of metabolic syndrome. Curr Opin Lipidol. 2015;26:73-81.
63. De Filippo C, Cavalieri D, Di Paola M, Ramazzotti M, Poullet JB, Massart S, Collini S, Pieraccini G, Lionetti P. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc Natl Acad Sci USA. 2010;107:14691-6.
64. Schwartz MW, Woods SC, Porte D Jr, Seeley RJ, Baskin DG. Review article Central nervous system control of food intake. Nature. 2000;404:661-71.
65. Zhang W, Cline MA, Gilber ER. Hypothalamus-adipose tissue crosstalk: neuropeptide Y and the regulation of energy metabolism. Nutr Metab (Lond). 2014;11:27.
66. Hall J, Silva AA, Carmo JM, Dubinion J, Hamza S, Munusamy S, Smith G, amd Stec S. Obesity-induced hypertension: role of sympathetic nervous system, leptin, and melanocortins. J Biol Chem 2010; 285(23):17271-6.
67. Gil JS, Drager LF, Guerra-Riccio GM, Mostarda C, Irigoyen MC, Costa-Hong V, Bortolotto LA, Egan BM, Lopes HF. The impact of metabolic syndrome on metabolic, pro-inflammatory and prothrombotic markers according to the presence of high blood pressure criterion. Clinics (Sao Paulo). 2013;68(12):1495-501.
68. Grassi G, Seravalle G, Cattaneo BM, Bolla GB, Lanfranchi A, Colombo M, Giannattasio C, Brunani A, Cavagnini F, Mancia G. Sympathetic activation in obese normotensive subjects. Hypertension 1995; 25(4Pt1):560-563.
69. Alvarez GE, Beske SD, Ballard TP, Davy KP. Sympathetic neural activation in visceral obesity. Circulation. 2002;106:2533-6.
70. Mark A. Selective leptin resistance revisited. Am J Physiol Regul Integr Comp Physiol. 2013;305:R566-81.
71. Landsberg L. Obesity, metabolism, and hypertension. Yale J Biol Med. 1989;62:511-9.
72. Scherrer U, Randin D, Tappy L, Vollenweider P, Jéquier E, Nicod P. Body fat and sympathetic nerve activity in healthy subjects. Circulation. 1994;89:2634-40.
73. Grassi G, Dell'Oro R, Facchini A, Trevano FQ, Bolla GB, Mancia G. Effect of central and peripheral body fat distribution on sympathetic and baroreflex function in obese normotensives. J Hypertens. 2004;22:2363-9.
74. Seravalle G, Colombo M, Perego P, Giardini V, Volpe M, Dell'Oro R, Mancia G, Grassi G. Long-term sympathoinhibitory effects of surgically induced weight loss in severe obese patients. Hypertension. 2014;64:431-7.
75. Després JP, Lemieux I, Prud'homme D. Treatment of obesity: need to focus on high risk abdominally obese patients. BMJ. 2001;322(7288):716-20.
76. Bartness TJ, Shrestha YB, Vaughan CH, Schvartz GJ, Song CK. Sensory and sympathetic nervous system control of white adipose tissue lipolysis. Mol Cell Endocrinol. 2009;318:34-43.
77. Kreier F, Fliers E, Voshol PJ, Eden CGV, Havekes LM, Kalsbeek A, et al. Selective parasympathetic innervation of subcutaneous and intra-abdominal fat - functional implications. J Clin Invest. 2002;110:1243-50.
78. Lafontan M, Berlan M. Fat cell adrenergic receptor and the control of white and brown fat cell function. J Lipid Res. 1993;34:1057-91.
79. Valet P, Grujic D, Wade J, Ito M, Zingarettii MC, Soloveva V, et al. Expression of human a2-adrenergic receptors in adipose tissue of b3-adrenergic receptor-deficient mice promotes diet-induced obesity. J Biol Chem. 2000;275:34797-802.